lobeglitazone + amlodipine

**Lobeglitazone + amlodipine** is a combination of the thiazolidinedione antidiabetic agent lobeglitazone and the dihydropyridine calcium channel blocker amlodipine. Lobeglitazone acts as an insulin sensitizer by binding and activating peroxisome proliferator-activated receptor gamma (PPARγ), improving glycemic control in type 2 diabetes mellitus, while amlodipine inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, thus lowering blood pressure. This combination would potentially target patients with coexisting type 2 diabetes and hypertension, addressing both glycemic and blood pressure control. No unique brand or code names for the fixed-dose combination are identified in the available literature; clinical data on coadministration indicate no clinically significant pharmacokinetic interactions, and both agents preserve their individual efficacy and safety profiles when given together[1][2].